Tonghe Pharmaceutical: First received the Australian TGA drug GMP certificate, valid until August 3, 2028.

Tonghe Pharmaceutical announced that the company recently received the Good Manufacturing Practice (GMP) compliance certificates for Mirabegron and Empagliflozin issued by the Australian Therapeutic Goods Administration (TGA). The certification covers the active pharmaceutical ingredients Mirabegron and Empagliflozin, with certificate number MI-2025-CE-02875-1, valid until August 3, 2028. This is the company's first successful GMP certification through the TGA, marking the qualification of the relevant active pharmaceutical ingredients for market access in Australia.